Amy M. Molan

658 total citations
9 papers, 406 citations indexed

About

Amy M. Molan is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Amy M. Molan has authored 9 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Immunology. Recurrent topics in Amy M. Molan's work include CAR-T cell therapy research (3 papers), HIV Research and Treatment (2 papers) and Virus-based gene therapy research (2 papers). Amy M. Molan is often cited by papers focused on CAR-T cell therapy research (3 papers), HIV Research and Treatment (2 papers) and Virus-based gene therapy research (2 papers). Amy M. Molan collaborates with scholars based in United States, United Kingdom and Netherlands. Amy M. Molan's co-authors include Reuben S. Harris, Gabriel J. Starrett, Brandon Leonard, William L. Brown, Emily K. Law, John W.M. Martens, Rachel I. Vogel, Kelly LaPara, Fred C.G.J. Sweep and Douglas Yee and has published in prestigious journals such as Nature Communications, Cancer Research and Science Advances.

In The Last Decade

Amy M. Molan

9 papers receiving 403 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy M. Molan United States	8	256	152	132	77	63	9	406
Adam Langenbucher United States	8	333 1.3×	118 0.8×	160 1.2×	73 0.9×	72 1.1×	12	463
Maya Isogai Japan	8	279 1.1×	181 1.2×	162 1.2×	90 1.2×	33 0.5×	11	497
Mia Petljak United States	7	408 1.6×	169 1.1×	279 2.1×	60 0.8×	99 1.6×	9	590
Sam H. Whiting United States	9	153 0.6×	141 0.9×	109 0.8×	76 1.0×	32 0.5×	20	361
Dona N. Ho Hong Kong	13	247 1.0×	137 0.9×	109 0.8×	53 0.7×	85 1.3×	18	485
Manuel Muñoz Spain	7	172 0.7×	288 1.9×	141 1.1×	79 1.0×	52 0.8×	15	502
Sandra Silva-Arrieta United States	7	223 0.9×	168 1.1×	127 1.0×	95 1.2×	147 2.3×	8	459
Cécile Desjobert France	13	357 1.4×	54 0.4×	143 1.1×	48 0.6×	40 0.6×	16	504
Zeping Luo United States	8	421 1.6×	209 1.4×	53 0.4×	59 0.8×	36 0.6×	8	581
Huseyin Saribasak United States	13	510 2.0×	99 0.7×	108 0.8×	349 4.5×	60 1.0×	18	828

Countries citing papers authored by Amy M. Molan

Since Specialization

Citations

This map shows the geographic impact of Amy M. Molan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy M. Molan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy M. Molan more than expected).

Fields of papers citing papers by Amy M. Molan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy M. Molan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy M. Molan. The network helps show where Amy M. Molan may publish in the future.

Co-authorship network of co-authors of Amy M. Molan

This figure shows the co-authorship network connecting the top 25 collaborators of Amy M. Molan. A scholar is included among the top collaborators of Amy M. Molan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy M. Molan. Amy M. Molan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Driscoll, Christopher B., Matthew Schuelke, Timothy Kottke, et al.. (2020). APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nature Communications. 11(1). 790–790. 49 indexed citations

2.

Evgin, Laura, Amanda L. Huff, Timothy Kottke, et al.. (2019). Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer Immunology Research. 7(5). 828–840. 13 indexed citations

3.

Ruis, Brian L., et al.. (2019). Absence of XRCC4 and its paralogs in human cells reveal differences in outcomes for DNA repair and V(D)J recombination. DNA repair. 85. 102738–102738. 14 indexed citations

4.

Brown, William L., Emily K. Law, Prokopios P. Argyris, et al.. (2019). A Rabbit Monoclonal Antibody against the Antiviral and Cancer Genomic DNA Mutating Enzyme APOBEC3B. Antibodies. 8(3). 47–47. 28 indexed citations

5.

Ikeda, Terumasa, Amy M. Molan, Matthew C. Jarvis, et al.. (2019). HIV-1 restriction by endogenous APOBEC3G in the myeloid cell line THP-1. Journal of General Virology. 100(7). 1140–1152. 15 indexed citations

6.

Huff, Amanda L., Phonphimon Wongthida, Timothy Kottke, et al.. (2018). APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy — Oncolytics. 11. 1–13. 19 indexed citations

7.

Molan, Amy M., Heather Hanson, Brett D. Anderson, et al.. (2017). APOBEC3B lysine residues are dispensable for DNA cytosine deamination, HIV-1 restriction, and nuclear localization. Virology. 511. 74–81. 2 indexed citations

8.

Law, Emily K., Anieta M. Sieuwerts, Kelly LaPara, et al.. (2016). The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Science Advances. 2(10). e1601737–e1601737. 160 indexed citations

9.

Leonard, Brandon, Jennifer L. McCann, Gabriel J. Starrett, et al.. (2015). The PKC/NF-κB Signaling Pathway Induces APOBEC3B Expression in Multiple Human Cancers. Cancer Research. 75(21). 4538–4547. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact